Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYang LiuMinistry of EducationGHGuang HuSoochow UniversityXMXiao‐Dong MoPeking University

Discussion

Loading...

Member takes

Overview

Comprehensive analysis reveals tumor microenvironment shifts and response indicators for immunotherapy in multiple myeloma patients.

Key Points

  • The study aims to explore the immune environment dynamics in multiple myeloma patients undergoing T cell redirecting therapies.
  • Analyzed a comprehensive single-cell atlas from 102 patients and 178 longitudinal samples.
  • Profiled 934,000 bone-marrow cells across different treatment stages after BCMA-CAR-T and BCMA-TCE.
  • Used STARTRAC analysis to assess clonal dynamics and immune activation specific to therapy.
  • T cell redirecting therapies lead to unique immune remodeling trajectories in patients with multiple myeloma.
  • Findings indicate differing responses in effector T cell populations between CAR-T and TCE therapies.
  • Established a predictive index to identify potential therapy failures and outcomes.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4echttps://doi.org/10.1182/blood-2025-7533
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma2025
  2. 2Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy2024 · 14 citations
  3. 3Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy2025
  4. 4Abstract 3617: Expansion and persistence of anti-BCMA CAR T cells correlates with durability of responses in multiple myeloma patients2024
  5. 5CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition2025